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Objective. We examined how quantity and trajectory of smoking reduction inﬂuence later abstinence in
smokers without intention to quit and being prescribed free nicotine replacement therapy (NRT).
Method. We conducted an a posteriori analysis from a data archive of adult smokers in a randomized
controlled trial of smoking reduction using counseling and free NRT (n= 928). Reduction was analyzed as the
absolute and percentage decrease in self-reported daily cigarette consumption at three follow-ups (1 week, 1
and 3 months) compared with the baseline. Logistic regression model and multiple imputation were used to
examine the association between early reduction and abstinence at 6 months.
Results. Reducing 10% of cigarette consumption at the three follow-ups was associated with 16% (95% CI
5–28%), 23% (95%CI 11–36%) and 27% (95% CI 13–42%) increase in abstinence, respectively. Greater reduction
predicted abstinence when the percentage reduction was more than one-third (above 31.4%). Progressive in-
crease in the percentage reduction predicted more abstinence (OR = 1.90, 95%CI 1.01–3.58).
Conclusions. Greater percentage reduction by at least one-third and progressive reduction predicted absti-
nence in those who reduced smoking. Such new evidence can guide the improvement of clinical service for
tobacco dependency treatment and support further studies on smoking reduction and cessation.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Smoking kills 6 million people each year in the world (World Health
Organization, 2011). Tobacco control interventions have successfully re-
duced the global smoking prevalence in the past decade, but the decline
has slowed down recently (Ng et al., 2014). To help smokers to quit,
smoking reduction is an alternative harm reduction strategy to reduce
ﬁrst with the assistance of nicotine replacement therapy (NRT) and be-
havioral counseling before abstinence.(National Institute for Health and
Clinical Excellence, 2013).
The review by Lindson-Hawley et al. (2012) summarized a few
mechanisms for smoking reduction and abstinence: from the view of
psychopathology, reduction in nicotine dose reduces drug dependence
andwithdrawal symptoms (Mooney et al., 2011); from the view of cog-
nitive psychology, smoking reductionmay increase self-efﬁcacy and the
likelihood to quit (Lindson-Hawley et al., 2012). While traditional
cessation strategies (e.g., motivational interviewing, stage-matchede University of Hong Kong, 5/F,
ng Kong. Fax:+852 2855 9528.
.
. This is an open access article underintervention)might not help some smokers to achieve cessation, reduc-
tion is appealing because making progression towards the goal of
complete cessation reﬂects visible behavioral change (Carpenter et al.,
2004). Experimental studies have found that smoking reduction inter-
vention combining medication and counseling is effective for smokers
without intention to quit (Asfar et al., 2011; Batra et al., 2005; Bolliger
et al., 2000; Carpenter et al., 2004; Chan et al., 2011; Rennard et al.,
2006; Shiffman et al., 2009; Wennike et al., 2003), but it is not clear
whether the increase in quitting is due to NRT availability, reduction it-
self, or both (Asfar et al., 2011).
Although a few studies have found the dose–response effect be-
tween reduction quantity and later abstinence (Broms et al., 2008;
Falba et al., 2004; Farkas, 1999; Hughes et al., 2004), these studies arbi-
trarily categorized reduction quantity and assumed a few thresholds of
reduction for cessation. Other associations such as curvilinear associa-
tion have not been examined.
The association between reduction quantity at one time point and
abstinence has been supported by a few prospective studies (Farkas,
1999;McDermott et al., 2008;Meyer et al., 2003), but no studies has ex-
amined the effect of continued reduction over a period of time. In real-
ity, smokers may either reduce cigarette consumption progressivelythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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duction. Progressively reducing smoking might help smoker perceive
that complete abstinence is achievable without abruptly changing
their current behavior (Lindson-Hawley et al., 2012).
The present a posteriori analysis, based on data from our previously
published RCT, which helped smokers without quitting intention to
use NRT for smoking reduction (Chan et al., 2011), aimed to examine
the association between the quantity of smoking reduction at the
follow-ups and abstinence at the ﬁnal follow-up. Our two research
questions were as follows: (1) What was the association between the
quantity of smoking reduction (measured in absolute and percentage
reduction) and the likelihood of later abstinence? (2) Did progressive
increase in the smoking reduction during the study period predict
later abstinence?
Materials and methods
Data
The archived data of 928 smokers recruited to the RCT and received
smoking reduction intervention during October 2004 to April 2007
were analyzed (Chan et al., 2011). The RCT aimed to examine the effec-
tiveness of smoking reduction counseling plus free NRT in the smokers
not willing to quit. All subjects were daily Chinese smokers who report-
ed no intention to quit in the near future butwere interested in reducing
smoking within the next 7 days. They were recruited through an-
nouncements in the local media and contacting previous cohorts of
smokerswho failed to quit in HongKong. Theywere randomly allocated
to two intervention groups and one control group by opening a serially
labeled, opaque and sealed envelopewith a card inside. All subjects pro-
vided written consent. The study was approved by the Institutional Re-
view Board of the Hong Kong West Cluster of Hong Kong Hospital
Authority (Ref. UW 03-103 T/103).
Intervention
Both intervention group A1 (n= 479) and A2 (n= 449) received a
15-min face-to-face counseling on smoking reduction by trained
smoking cessation counselors and free NRT for eight weeks in total
(Supplementary material 1). The counseling for groups A1 and A2 em-
phasized that the goal of smoking reduction was abstinence. Trained
counselors advised the participants the importance of smoking reduc-
tion, how reduction is useful and effective when quitting is difﬁcult,
and how to develop a tailored smoking reduction schedule. The coun-
selors in the trial advised the participants to increase reduction at 1-
week and 1-month follow-up, but the participants had the autonomy
to alter their reduction amount. In addition, group A1 also received 3-
min counseling of adherence to NRT, which followed the guidelines on
adherence interventions by the World Health Organization (World
Health Organization, 2003) (Supplementarymaterial 2 and 3). The con-
trol group only received a 10-min brief advice on the health hazards of
smoking and the importance of smoking cessation at baseline only. All
the participants of the 3 groups were given a 12-page self-help quitting
pamphlet, “Tips for Quit Smoking,” produced by Hong Kong Council on
Smoking and Health. The present analysis included the subjects in
groups A1 and A2 as they were followed up at 1 week, 1 month,
3 months and 6 months.
Outcome measurements
All subjects were asked if they smoked in the past 7 days at all
follow-ups for the primary outcome of the point prevalence of absti-
nence. For those who reported smoking in the past 7 days at the
1-week follow-up, they were then asked the mean daily cigarette
consumption in the past week. Participants who reported smoking
at 1-, 3- and 6-month follow-up were asked about their mean dailycigarette consumption in the past month. Participants were classiﬁed
as reducers at a particular follow-up if the number of self-reported
daily cigarette consumption was less than baseline. At the 1-week and
1-month face-to-face follow-up, exhaled carbon monoxide (CO) and
urinary cotinine level were collected. Self-reported quitters who re-
ported no smoking in the past 7 days at the 6-month follow-upwere in-
vited for the biochemical veriﬁcation. Validated quitters were identiﬁed
if their exhaled COwas less than 9 parts permillion and urinary cotinine
concentration was less than 115 ng/ml.Covariates
Demographic information, including gender, age, household income
andwhether livingwith children at home, was enquired. Self-perceived
importance, difﬁculty and conﬁdence to reduce were assessed with the
following questions on a rating scale from 0 to 100: (1) How important
is it for you to reduce smoking? (2) How much difﬁculty do you think
you will have in reducing smoking? (3) How much conﬁdence do you
have that youwill be able to reduce smoking by at least 50% of your cur-
rent level? Smoking-related information included whether having pre-
vious quit attempt in lifetime, years of daily smoking, daily cigarette
consumption (b15 versus ≥15) and 6-item Fagerstrom Test for Nicotine
Dependence (Heatherton et al., 1991). We assessed the adherence to
NRT at the 1-week, 1-month and 3-month follow-up by enquiring if
they had ever consumed or consumed all the NRT prescribed at the pre-
vious follow-up. Treatment condition (group A1 versus group A2) was
also included as an adjustment factor.Data analysis
The percentage reduction was calculated by dividing the difference
of daily cigarette consumption between baseline and a particular
follow-up by the number of cigarettes consumed at baseline. Descrip-
tive statistics about the reduction quantity by different smoking status
and reduction at all follow-ups are shown in Table 2. Multiple logistic
regression models were used to examine the predictive power of abso-
lute and percentage reduction on the 6-month abstinence in the partic-
ipants who had not quit at those follow-ups. Each model examined the
reduction quantity at oneparticular follow-up, in absolute or in percent-
age reduction, to predict the 6-month abstinence. All the models were
adjusted for treatment condition (group A1 versus group A2), baseline
demographic, smoking characteristics and adherence to NRT. To test
the curvilinear association between reduction and cessation, quadratic
transformation of the absolute and percentage reduction was included
in the models. Wald test of the regression coefﬁcient for the quadratic
term was conducted. If the coefﬁcient was signiﬁcant, a scatterplot
and a ﬁtted quadratic line were used to demonstrate the curvilinear
association.
The second set of regression model estimated the predictive power
of increasing reduction from 1-week to 3-month follow-up on the 6-
month abstinence in four separate regressionmodels, where the predic-
tors included (1) smokers with increased reduction from 1 week to
1 month, (2) smokers with increased reduction from 1 month to
3 months, (3) smokers with increased reduction from 1 week to
3 months and (4) smokers with increased reduction throughout the
three follow-ups. The reference group in these regression models in-
cluded participants who reported no increase in smoking reduction.
To provide more robust estimate with missing values of cigarette
consumption due to loss to follow-up, Markov Chain Monte Carlo
(MCMC) was used to implement multiple imputation procedure for
themissing values (Rubin, 2004; Schafer, 1997). The imputation gener-
ated 20 data sets with imputed missing data with the factors relating to
cigarette consumption in 1-week, 1-, 3- and 6-month follow-up. All the
data analysis were conducted with SAS version 9.2.
Table 1
Baseline characteristics of the participants in the intervention groups (all participants, groups A1 and A2).
All (n= 928) Group A1 (n= 479) Group A2 (n= 449)
Sex, n(%) Male 748 (80.6) 373 (77.9) 375 (83.5)
Female 180(19.4) 106 (22.1) 74 (16.5)
Age, mean ± SD, years 41.9 ± 10.3 41.5 ± 10.3 42.4 ± 10.3
Marital status, n(%) Married/cohabiting 658(70.9) 323 (67.4) 335 (74.8)
Others 270(29.1) 156 (32.6) 113 (25.2)
Education level, n(%) Primary or below 101(10.9) 53 (11.1) 48 (10.7)
Secondary 608(65.5) 331 (69.1) 329 (73.4)
Tertiary or above 218(23.5) 95 (19.8) 71 (15.8)
Age started smoking, mean ± SD, years 17.8 ± 4.7 18.0 ± 4.6 17.5 ± 4.8
Years of regular smoking, mean ± SD 24.1 ± 10.4 23.5 ± 10.8 24.8 ± 9.9
Daily cigarette consumption, mean ± SD 19.9 ± 9.8 19.8 ± 9.4 20.1 ± 10.1
Fagerstrom Nicotine Dependence Score, mean ± SD 5.2 ± 2.3 5.3 ± 2.3 5.2 ± 2.4
Lifetime quit attempt before trial, n(%) None 204(22.0) 104 (21.8) 100 (22.4)
1 attempt 266(28.7) 144 (30.1) 122 (27.4)
2 to 5 attempts 370(39.9) 178 (37.2) 192 (43.0)
6 to 10 attempts 32(3.4) 21 (4.4) 11 (2.5)
more than 10 attempts 52(5.6) 31 (6.5) 21 (4.7)
Used nicotine replacement therapy before trial, n(%) 359(38.7) 193 (40.3) 166 (37.1)
Importance in reducting smoking, mean ± SD 82.7 ± 17.2 82.8 ± 17.3 82.5 ± 17.2
Difﬁculty in reducing smoking, mean ± SD 69.4 ± 22.2 69.0 ± 22.7 69.8 ± 21.7
Conﬁdence in reducing smoking, mean ± SD 64.1 ± 20.3 64.9 ± 20.1 63.3 ± 20.5
Choice of NRT in the study, n(%) Patch (15 mg) 578(62.3) 306 (64.0) 272 (60.6)
Gum (2 mg) 257(27.7) 133 (27.8) 124 (27.6)
Gum(4 mg) 89(9.6) 39 (8.2) 50 (11.1)
Refused to use NRT when offered 3 (0.4) 0 (0.0) 3 (0.6)
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No signiﬁcant difference in the socio-demographic and smoking
characteristics between groups A1 and A2 at the baseline was found.
The proportions of using NRT patch and gum for the intervention
were 61.2% and 38.7%, respectively (Table 1). Over 60% of the partici-
pants had reduced smoking in each follow-up (Table 2). The quit rate
increased progressively from 2.3% at 1 week to 16.9% at 6 months. Any
use of NRT since baseline when asked at the 1-week, 1-month and 3-
month follow-up was 85.2%, 75.8% and 82.4%, respectively. The self-
reported complete adherence of NRT at all the follow-up was over
50%. It was associated with higher percentage reduction at all the
follow-ups, but was not associated with abstinence (Supplementary
material 4). The regression models were adjusted for complete NRT ad-
herence, socio-demographic and smoking characteristics at baseline.
Exhaled CO values decreased as the participants reduced more
cigarettes.
From the regression analysis, there was about 3–5% increase in the
odds of abstinence per 1 cigarette reduced at 1-week, 1-month or 3-
month follow-up compared to baseline (Table 3). Reducing 10% of ciga-
rette consumption at the three follow-ups was associated with 16%
(95% CI 5–28%), 23% (95%CI 11–36%) and 27% (95% CI 13–42%) increase
of the odds of abstinence at 6-month follow-up, respectively (Table 3).
The dose–response effect was signiﬁcant for reductions at all follow-
up, except 1-week absolute reduction. Percentage reduction and later
follow-up had better goodness of ﬁt than absolute reduction and early
follow-up (Fig. 1).
Curvilinear association between reduction and abstinence was
assessed by adding a quadratic term of reduction quantity in each re-
gression model. Small magnitudes of all quadratic termswere observed
(Beta b 0.001). Only the quadratic term of 1-month absolute
(Beta = −0.00387, p = 0.02), and 3-month percentage reduction
(Beta = 0.00063, p b 0.01) was signiﬁcant (Table 3). The scatter plot
of predicted probability against reduction showed the linear relation-
ship for the absolute and percentage reduction at 1week, percentage re-
duction at 1 month and absolute reduction at 3 months and the
curvilinear association for the absolute reduction at 1 month and per-
centage reduction at 3 months. In the regression model with the qua-
dratic term of 3-month percentage reduction, the inﬂection point for
the ﬁtted curve was 31.4%, indicating the positive association betweenpercent reduction and abstinence when the percent reduction was
higher than 31.4%.
Participants who increased the reduction at 1 month (com-
pared with 1-week reduction) and 3 months (compared with
reduction at 1 week and 1 month) had an insigniﬁcantly higher
quit rate than those who maintained or decreased the percent-
age reduction (Table 4). Progressive increase in reduction from
the 1-week to 3-month follow-up signiﬁcantly increased the
odds of abstinence (OR = 1.90, 95%CI = 1.01–3.58).
Discussion
The present study showed the overall dose–response relationship
between reduction and abstinence in smokers who had no intention
to quit and received free NRT, which was consistent with previous co-
hort studies which targeted all smokers (Falba et al., 2004; Farkas,
1999; Hughes et al., 1999, 2004). Greater and progressive reduction
may be associated with higher motivation to quit, whichwas suggested
as a moderator between reduction and cessation (Cheong et al., 2007).
However, the goodness of ﬁt in the linear models was relatively poor
when early reduction and absolute reduction in cigarettes were consid-
ered. The dose–response effect of percentage reductionwasmore stable
than absolute reduction, and the latter was consistent with another
study that the absolute reduction of cigarettes was not associated with
quit rate (Farkas, 1999). Smokers with large absolute reduction might
have large cigarette consumption at baseline, which would confound
the dose–response relationship between absolute reduction and absti-
nence. The percentage reduction at 3-month and abstinence at 6-
month had a curvilinear relationship, such that greater reduction pre-
dicted abstinence when the percentage reduction was more than one-
third. The predicted probability of abstinence was very low (below
0.1) when the percent reduction was below 31.4%, which suggested
that too small a reduction does not help reduce the nicotinedependence
(Lindson-Hawley et al., 2012; Mooney et al., 2011). Also, smokers who
received intensive intervention but reduced only a little might have a
lowermotivation to continue the quitting process and thus a lower like-
lihood to quit successfully.
The present study provided preliminary evidence that smokers who
increased their percentage reduction progressively were more likely to
quit eventually than those who did not reduce or did not increase their
Table 2
Smoking and quitting status of participants at follow-ups (n= 928).
1 week 1 month 3 months 6 months
n % n % n % n %
Smoking status (compared to baseline)
No reduction 31 3.3 34 3.7 76 8.2 113 12.2
Reduced smoking 748 64.8 658 70.9 615 66.3 561 60.5
Quitted smoking 26 2.3 44 4.7 105 11.3 157 16.9
Missing/lost to follow-up 123 10.7 192 20.7 132 14.2 97 10.5
Mean number of daily cigarettes
(SD) (All smokers)
11.8 (7.0) 10.1 (6.9) 10.2 (7.4) 11.6 (7.8)
Mean number of daily cigarettes
(Reducers only)
11.6 (6.8) 9.7 (6.5) 9.0 (6.1) 10.1 (6.4)
Mean % cigarette reduction
compared with baseline
(SD) (Reducers only)
42.3
(18.5)
52.0
(20.1)
55.7
(22.2)
49.0
(22.4)
Cigarette reduction
1–24.9% 127 17.0 61 9.3 55 8.9 69 11.4
25–49.9% 342 45.7 219 33.3 147 23.9 204 33.7
50–74.9% 235 31.4 281 42.7 271 44.1 241 39.8
75–99.9% 44 5.9 97 14.7 142 23.1 91 15.0
Used any prescribed NRT⁎ 791 85.2 703 75.8 765 82.4 NA NA
Used all prescribed NRT⁎⁎ 542 58.4 483 52.1 498 53.7 NA NA
Mean exhaled carbon monoxide (parts per million) (SD)
No reduction 13.6 (8.1) 12.3 (8.0) NA NA NA NA
Reduced smoking 1–24.9% 16.9 (9.5) 14.6 (9.2) NA NA NA NA
Reduced smoking 25–49.9% 14.4
(7.7)+
13.3 (7.5) NA NA NA NA
Reduced smoking 50–74.9% 11.0
(7.9)++
10.8
(8.0)++
NA NA NA NA
Reduced smoking 74.9–99.9% 8.3
(7.2)++
4.5
(4.5)+++
NA NA NA NA
Quitted smoking 2.1
(1.3)+++
1.9
(1.4)+++
NA NA NA NA
Mean urine cotinine (ng/ml) (SD)
No reduction 5.5 (0.8) 5.0 (1.7) NA NA NA NA
Reduced smoking 1–24.9% 5.6 (0.5) 5.4 (1.0) NA NA NA NA
Reduced smoking 25–49.9% 5.6 (0.7) 5.5 (1.0) NA NA NA NA
Reduced smoking 50–74.9% 5.4 (0.9) 5.3 (0.9) NA NA NA NA
Reduced smoking 75–99.9% 4.9
(1.1)++
5.1 (1.0) NA NA NA NA
Quitted smoking 3.8
(2.0)+++
3.6
(1.2)+++
NA NA NA NA
***Independent t-test showed that the readings of exhaled carbon monoxide and uri-
nary cotinine were signiﬁcantly different from the group of “reduced smoking
1–24.9%” (+p b 0.05; ++p b 0.01; +++p b 0.001).
⁎ 1-week follow-up: any use of prescribed NRT in the past 7 days; 1-month follow-up:
any use of prescribed NRT in the past month; 3-month follow-up: any use of prescribed
NRT in the past 3 months.
⁎⁎ 1-week follow-up: Used all NRT in the past 7 days; 1-month follow-up: Used all NRT
in the past month; 3-month follow-up: Used all NRT in the past 3 months.
Table 3
Odds ratios and regression coefﬁcients of abstinence at 6 months by smoking reduction quanti
Follow-up time Predictor Adju
1-week
(n= 748)
Per 1 cigarette reduced 1.03
Per 10% cigarette reduced 1.16
Quadratic term of cigarette reduction
Quadratic term of percentage reduction
1-month (n= 658) Per 1 cigarette reduced 1.05
Per 10% cigarette reduced 1.23
Quadratic term of cigarette reduction
Quadratic term of percentage reduction
3-month (n= 615) Per 1 cigarette reduced 1.03
Per 10% cigarette reduced 1.27
Quadratic term of cigarette reduction
Quadratic term of percentage reduction
Adjusted variables: gender, age, household income group, previous quit attempt, self-perceive
Dependence, living with children at home, years of daily smoking, daily cigarette consumption
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gressive increase in the reduction quantity may increase self-efﬁcacy
and thereby their motivation to quit eventually (Lindson-Hawley
et al., 2012). Only the smokers who could maintain and increase reduc-
tion at all follow-ups showed more abstinence signiﬁcantly because
they showed a higher persistency in reducing smoking towards the ces-
sation goal. In the reference groups of the regression models in Table 4,
some smokers might have quit abruptly without going through the re-
duction process, which might reduce the inﬂuence of reduction.
Given the current evidence, NRT-aided smoking reduction is an ef-
fective quitting strategy in smokers with no intention to quit. They
should be given structured assistance to reduce by at least one-third
and increase the reduction throughout thepre-quit period.More impor-
tantly, before recommending any strategies to the smokers, counselors
should understand the smokers’motivation to quit and perceived difﬁ-
culty to reduce. If the strategy of smoking reduction is applicable, coun-
selors should design scheduled targets of reduction and discuss how to
adhere to the schedule with the smoker.
The present study was the ﬁrst to examine the association between
smoking reduction and cessation in a large sample of Chinese smokers
who had no intention to quit. Instead of arbitrary categorization of re-
duction quantity, we regressed on both absolute and percentage reduc-
tion as continuous variables to predict the outcomes. Both linear and
curvilinear associations were examined. However, there were a few
limitations. The current analysis relied on self-reported cigarette con-
sumption of the participants at each follow-up, which might be subject
to recall bias. The level of exhaled carbon monoxide of the participants
wasmeasured at 1-week and 1-month follow-up, but it might be affect-
ed by the temporal proximity to recent smoking and could not validate
reduction. Hence, we used the self-reported number of cigarettes
smoked as the unit of analysis. At the ﬁnal follow-up, because biochem-
ical validation of abstinence was voluntary, only 84 of the 181 quitters
(46.4%) participated. A major limitation of the present study was that
validated abstinence was not the primary outcome. Second, the present
studydid not address the rate of smoking reduction. Smokerswho could
quickly reduce cigarette consumption might be more capable to handle
withdrawal symptoms and had a higher likelihood to quit. Lastly, the
study design did not provide sufﬁcient evidence for the casual relation-
ship of greater reduction and abstinence. An RCT allocating smokers to a
large or a small reduction intervention is more appropriate to test the
difference.
Conclusion
This a posteriori analysis of RCT data found that greater reduction in
smoking predictedmore abstinence in smokerswhohad no intention to
quit and had used NRT. Progressively increasing the percentage reduc-
tion during the pre-quit period was predictive of more abstinence.
Such new evidence can guide the improvement of clinical service forty (excluding participants lost to follow-up and quitters at follow-ups).
sted OR of abstinence (95%CI) Regression coefﬁcient p-value
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Fig. 1. Scatterplot of the predicted probability of 6-month abstinence against reduction of cigarette consumption at 1-week, 1-month and 3-month follow-up.
Table 4
Quit rate at 6-month follow-up by increasing percentage reduction (excluding partici-
pants lost to follow-up and quitters at follow-ups).
Increased reduction in daily cigarette
consumption, follow-up time
Quit rate at
6-month
Adj. OR (95% CI) p-value
1-month N 1-week (n= 639) Yes 68/416 (16.3%) 1.31 (0.80, 2.14) 0.28
No⁎ 29/223 (13.0%)
3-month N 1-month (n= 555) Yes 27/257 (10.5%) 1.57 (0.89, 2.77) 0.12
No⁎ 22/298 (7.4%)
3-month N 1-week (n= 607) Yes 39/369 (10.6%) 1.58 (0.88, 2.82) 0.12
No⁎ 19/238 (8.0%)
3-month N 1-month N 1-week
(n= 517)
Yes 20/154 (13.0%) 1.90 (1.01, 3.58) 0.04
No⁎ 26/363 (7.2%)
Adjusted variables: gender, age, household income group, previous quit attempt, self-
perceived importance, difﬁculty and conﬁdence to reduce smoking, Fagerstrom Test for
Nicotine Dependence, livingwith children at home, years of daily smoking, daily cigarette
consumption ≥ 15, and adherence to NRT during the follow-up period.
⁎ The reference group included those reducers who did not increase percentage reduc-
tion, or had the same percentage reduction as previous.
200 Y.T.D. Cheung et al. / Preventive Medicine Reports 2 (2015) 196–201tobacco dependency treatment and support further studies on smoking
reduction and cessation.
Clinical trial registration number: ISRCTN05172176 (http://www.
controlled-trials.com).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.pmedr.2015.02.014.
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